DRREDDY

Dr. Reddys Laboratories Ltd.

NSE: DRREDDY

BSE: 500124

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,370.70+25.0 (+1.86%)

3 Jul, 10:59 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

69.4 / 100

Value Score

61.4 / 100

Price Momentum Score

77.3 / 100

QVM Score

87.5 / 100

Key Metrics

Market Cap

1,12,058 Cr

P/E (TTM)

26.71

P/B

2.96

P/S (TTM)

3.33

EV/EBITDA

15.92

CAPE (5Y)

25.35

ROE (TTM)

11.75

ROCE (TTM)

11.53

ROA (TTM)

7.80

Avg 3Y ROE

17.23

Earnings 3Y CAGR

-2.41

Sales 3Y CAGR

10.96

Sales 5Y CAGR

12.09

Debt/Equity

0.20

Consensus TP

1300.00

Strong Buy %

15.79

Promoter Holding

26.63

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Dr. Reddys Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 77.3 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

77.3 / 100

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.2 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.06 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Analysts have been downgrading forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has decreased by -4.62% in the last 3 months, indicating weak earnings momentum

What is Earnings upgrade (3M)?

Moderate ROE but declining trend

The company reported moderate ROE of 11.75% for 12-month ended 31 Mar 2026 but ROE declined by -655 bps from 1 year ago

What is ROE (FY)?

Moderate operating margin but declining trend

The company reported moderate operating margin of 14.47% for 12-month ended 31 Mar 2026 but operating margin declined by -701 bps from 1 year ago

What is Operating profit margin?

Low revenue growth and lower than median growth of industry

The company delivered moderate revenue growth of 3.24% for 12-month ended 31 Mar 2026 and the growth was 8.0 percentage points lower than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 3.24

-82.35114662

Low EPS growth and lower than median growth of industry

The company delivered moderate EPS growth of -25.73% for 12-month ended 31 Mar 2026 and the growth was 33.85 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.59%

What is Dividend yield?

Neutral

Stock appears expensive but is at a discount to industry median P/E

PE TTM of 26.71 indicates that the stock is expensive on a standalone basis but discount to industry median P/E is decent at -11.73%

What is P/E Ratio?

Median: 30.26

Value 26.71

-215.443183

Company's earnings are of moderate quality

Earnings quality score of 60.2 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

60.2 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Dr. Reddys Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Dr. Reddys Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Dr. Reddys Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	26.75	26.74	26.74	26.73	26.74	26.73	26.72	26.72	26.72	26.71	26.71	26.70	26.70	26.69	26.66	26.65	26.65	26.65	26.64	26.64	26.64	26.64	26.64	26.64	26.63
Indian Promoter	26.75	26.74	26.74	26.73	26.74	26.73	26.72	26.72	26.72	26.71	26.71	26.70	26.70	26.69	26.66	26.65	26.65	26.65	26.64	26.64	26.64	26.64	26.64	26.64	26.63
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	44.50	43.97	43.50	43.86	43.93	44.78	49.16	49.71	49.94	51.05	50.95	61.20	50.30	48.98	49.23	47.27	47.44	48.41	49.01	49.74	51.37	52.07	52.67	52.78	51.86
Mutual Funds / UTI	8.75	9.96	11.37	13.28	13.31	12.42	12.17	12.47	14.12	14.21	12.84	10.94	9.87	9.31	8.61	8.22	7.96	10.05	10.86	11.14	12.89	13.61	13.31	13.87	13.19
FI/Bank/Insurance	5.49	4.53	2.38	1.05	0.94	2.66	8.75	9.48	10.35	10.74	11.62	12.25	13.01	12.57	10.15	7.99	7.79	7.99	7.86	9.12	10.18	10.60	11.93	14.06	14.70
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	30.15	29.33	29.58	29.13	29.03	29.04	27.76	27.42	25.16	25.87	26.26	27.29	27.25	26.99	28.19	28.62	29.13	27.68	27.53	26.85	25.75	25.33	24.69	22.34	21.14
Other Institutions	0.11	0.15	0.17	0.39	0.66	0.65	0.48	0.34	0.32	0.24	0.23	10.72	0.17	0.11	2.28	2.44	2.56	2.68	2.76	2.63	2.56	2.52	2.75	2.51	2.83
Non-Institution	14.65	15.27	15.66	16.29	17.13	16.40	12.07	12.04	12.12	11.87	12.26	12.10	11.70	11.78	10.09	10.75	10.55	10.36	10.13	10.38	10.44	10.26	9.86	9.71	9.57
Bodies Corporate	4.40	4.92	5.25	5.42	5.23	5.19	0.54	0.60	0.46	0.38	0.39	0.49	0.38	0.37	0.42	0.49	0.47	0.44	0.40	0.37	0.37	0.35	0.36	0.31	0.34
Others (incl. Retail) No. of shareholders	10.25 1,13,678	10.35 1,29,470	10.41 1,51,228	10.87 1,77,257	11.90 2,18,933	11.21 2,21,106	11.53 2,53,588	11.44 2,40,251	11.66 2,61,734	11.49 2,53,240	11.87 2,57,196	11.61 2,44,774	11.32 2,30,738	11.41 2,44,348	9.67 2,40,600	10.26 2,54,777	10.08 2,52,536	9.92 2,64,797	9.73 3,07,684	10.01 4,01,158	10.07 4,57,053	9.91 4,49,574	9.50 4,47,100	9.40 4,53,178	9.23 4,47,614

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Pharma	8.93%	3 / 20
2	Nifty Healthcare	7.66%	4 / 20
3	Nifty 100 Low Volatility 30	3.24%	19 / 30
4	Nifty100 Quality 30	3.09%	20 / 30
5	Nifty Alpha Low Vol 30	3.02%	24 / 30
6	Nifty50 Value 20	1.96%	18 / 20
7	Nifty 50 Equal Weight	1.92%	28 / 50
8	Nifty 100 Equal Weight	0.94%	66 / 100
9	Nifty 50	0.73%	44 / 50
10	Nifty 100	0.61%	47 / 100

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Dr. Reddys Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
C Swaminathan Designated Person	October-2021	Market Sale (Disposal) 4th Oct 2021	0.00 %	₹ 4,822.43	489.00	₹ 23.58 lac
Dr. Reddy's Employees ESOS Trust Trust	September-2021	Off Market (Disposal) 30th Sep 2021	0.29 %	₹ 4,819.19	3.48 k	₹ 1.67 cr
Dr. Reddy's Employees ESOS Trust Trust	September-2021	Market Sale (Disposal) 29th Sep 2021	0.30 %	₹ 4,798.18	758.00	₹ 36.37 lac
Dr. Reddy's Employees ESOS Trust Trust	September-2021	Off Market (Disposal) 29th Sep 2021	0.30 %	₹ 4,808.75	432.00	₹ 20.77 lac
Sanjay Sharma Designated Person	September-2021	Market Sale (Disposal) 29th Sep 2021	0.00 %	₹ 4,910.00	1.00 k	₹ 49.10 lac
Arun Anand Immediate Relative	September-2021	Market Sale (Disposal) 27th Sep 2021	0.00 %	₹ 4,790.00	300.00	₹ 14.37 lac
Dr. Reddy's Employees ESOS Trust Trust	September-2021	Market Sale (Disposal) 27th Sep 2021	0.30 %	₹ 4,805.99	374.00	₹ 17.97 lac
Dr. Reddy's Employees ESOS Trust Trust	September-2021	Off Market (Disposal) 27th Sep 2021	0.30 %	₹ 4,811.20	301.00	₹ 14.48 lac
Bijaygopal Chakrabarti Designated Person	September-2021	Market Sale (Disposal) 24th Sep 2021	0.00 %	₹ 4,856.65	705.00	₹ 34.24 lac
Dr. Reddy's Employees ESOS Trust Trust	September-2021	Market Sale (Disposal) 24th Sep 2021	0.30 %	₹ 4,838.02	585.00	₹ 28.30 lac

…

Corporate Actions

History of Dr. Reddys Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 8/share
Record date: 10th Jul 2026Ex-date: 10th Jul 2026
Announced on: 12th May 2026
Dividend₹ 8/share
Record date: 10th Jul 2025Ex-date: 10th Jul 2025
Announced on: 9th May 2025
Stock Split1 : 5
Ex-date: 28th Oct 2024Announced on: 27th Jul 2024
Nominal value change from INR 5 to INR 1.
Dividend₹ 40/share
Record date: 16th Jul 2024Ex-date: 16th Jul 2024
Announced on: 7th May 2024
Dividend₹ 40/share
Record date: 11th Jul 2023Ex-date: 11th Jul 2023
Announced on: 10th May 2023

Company Profile

Overview of Dr. Reddys Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of...

Key personnel

Mr. Erez Israeli

Chief Executive Officer

Mr. Mannam Venkata Narasimham

Chief Financial Officer

Milan Kalawadia

Chief Executive Officer, North America

Mr. M. V. Ramana

Chief Executive Officer - Global Generics

Mr. Deepak Sapra

Chief Executive Officer - API and Services

Mr. Sanjay Sharma

Chief Operating Officer

Mr. Phanimitra (Phani) B

Chief Digital and Information Officer

Mr. K. Randhir Singh

Compliance Officer, Company Secretary, Head - CSR

View all

Incorporated on

24 Feb 1984

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

27,527

IPO date

01 Jan 1986

Free Float

58,48,48,199

Website

https://www.drreddys.com/

Phone no.

+914049002900

Address

8-2-337, Road No.3 Banjara Hills, HYDERABAD, 500-034, India

Frequently Asked Questions

What is the current share price of Dr. Reddys Laboratories Ltd.?

The current share price of Dr. Reddys Laboratories Ltd. is ₹ 1,370.70 as of 3 Jul 2026.

What is the market capitalisation of Dr. Reddys Laboratories Ltd.?

The market capitalisation of Dr. Reddys Laboratories Ltd. stands at ₹ 1,12,058.00 Cr.

What is the PE ratio of Dr. Reddys Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Dr. Reddys Laboratories Ltd. is 26.71 as of the latest trailing twelve months data.

What is the ROE and ROCE of Dr. Reddys Laboratories Ltd.?

Dr. Reddys Laboratories Ltd. has a Return on Equity (ROE) of 11.75% and a Return on Capital Employed (ROCE) of 11.53% as per the latest financial reports.

What is the 52-week high and low of Dr. Reddys Laboratories Ltd.?

The 52-week high of Dr. Reddys Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Dr. Reddys Laboratories Ltd.?

The dividend yield of Dr. Reddys Laboratories Ltd. is 0.59% based on the current market price.

What is the FII and DII holding in Dr. Reddys Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 21.14%, Domestic Institutional Investors (DII) hold 27.89% and retail/public investors hold 9.23% of Dr. Reddys Laboratories Ltd. shares.

What sector does Dr. Reddys Laboratories Ltd. belong to?

Dr. Reddys Laboratories Ltd. operates in the Healthcare sector. 47.37% of analysts have a Buy or Strong Buy rating on Dr. Reddys Laboratories Ltd. with a consensus target price of ₹ 1,300.00, implying 3.4% downside from current levels.

What is the beta of Dr. Reddys Laboratories Ltd.?

The beta of Dr. Reddys Laboratories Ltd. is 0.53, indicating its price volatility relative to the broader market. Over the past 1 year, Dr. Reddys Laboratories Ltd. has delivered an absolute return of 0.63%.

What is the RSI of Dr. Reddys Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Dr. Reddys Laboratories Ltd. is 61.44, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Dr. Reddys Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Dr. Reddys Laboratories Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Company Profile

Corporate Actions